Etoposide inhibits the EMT/β-catenin/STT1/PD-L2 signalling axis through TOP3B-dependent β-catenin degradation, leading to downregulation of PD-L1 in breast cancer stem cells (CSCs) and non-stem cells (non-CSCs). Here, CD274 is linked to breast cancer.